中国儿童银屑病生物治疗专家共识（2021）

doi:10.35541/cjd.20210547

Abstract

Abstract: 【Abstract】 For moderate to severe pediatric psoriasis, if disease condition cannot be controlled by topical treatments, systemic treatments should be considered in clinical practice. Children are a special population for the application of biologics, and different from adults in terms of dosage, efficacy, and safety of biologics. Based on Chinese and international guidelines and consensus, relevant literature and current clinical experience, a group of experts in the field of pediatric psoriasis developed this consensus after in-depth discussions. This consensus provides guidance regarding application principles and methods, efficacy and safety, and treatment duration of biologics, as well as time-to-withdrawal, pre-treatment screening and treatment monitoring. It is hoped that this consensus will provide a reference for rational application of biologics among children with moderate to severe psoriasis in China.

Key words: Psoriasis, Biological agents, Child, Treatment, Consensus

Group on Children, Chinese Society of Dermatology, Group on Pediatric Dermatology, China Dermatologist Association, Dermatology and Venereology Group, Chinese Pediatric Society, Chinese Medical Association, Pediatric Dermatology Rehabilitation Group, Chinese Association of Rehabilitation Dermatology. Treatment of pediatric psoriasis with biological agents: a Chinese expert consensus statement （2021） [J].Chinese Journal of Dermatology, 2021,54(11):943-950.

References ［46］

［1］	Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review［J］. Int J Mol Sci, 2020,21（5）:1690. doi: 10. 3390/ijms21051690.
［2］	Fotiadou C, Lazaridou E. Psoriasis and uveitis: links and risks［J］. Psoriasis （Auckl）, 2019,9:91⁃96. doi: 10.2147/PTT.S179182.
［3］	Alsenaid A, Ezmerli M, Srour J, et al. Biologics and small molecules in patients with scalp psoriasis: a systematic review［J］. J Dermatolog Treat, 2020:1⁃10. doi: 10.1080/09546634.2020. 1770167.
［4］	Misiak⁃Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments［J］. Am J Clin Dermatol, 2020,21（3）:355⁃370. doi: 10.1007/s40257⁃020⁃00503⁃5.
［5］	Smith MP, Ly K, Thibodeaux Q, et al. Acrodermatitis continua of Hallopeau: clinical perspectives［J］. Psoriasis （Auckl）, 2019,9:65⁃72. doi: 10.2147/PTT.S180608.
［6］	Bardazzi F, Starace M, Bruni F, et al. Nail psoriasis: an updated review and expert opinion on available treatments, including biologics［J］. Acta Derm Venereol, 2019,99（6）:516⁃523. doi: 10.2340/00015555⁃3098.
［7］	Micali G, Verzì AE, Giuffrida G, et al. Inverse psoriasis: from diagnosis to current treatment options［J］. Clin Cosmet Investig Dermatol, 2019,12:953⁃959. doi: 10.2147/CCID.S189000.
［8］	Ollech A, Zvulunov A, Pavlovsky L, et al. Biologic treatment of recalcitrant pediatric psoriasis: a case series from a tertiary medical center［J］. J Dermatolog Treat, 2019,30（2）:152⁃155. doi: 10.1080/09546634.2018.1476655.
［9］	Bronckers I, Seyger M, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis［J］. JAMA Dermatol, 2017,153（11）:1147⁃1157. doi: 10.1001/jamadermatol.2017.3029.
［10］	Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis［J］. N Engl J Med, 2008,358（3）:241⁃251. doi: 10.1056/NEJMoa066886.
［11］	Paller AS, Siegfried EC, Pariser DM, et al. Long⁃term safety and efficacy of etanercept in children and adolescents with plaque psoriasis［J］. J Am Acad Dermatol, 2016,74（2）:280⁃287. doi: 10.1016/j.jaad.2015.09.056.
［12］	Foeldvari I, Constantin T, Vojinović J, et al. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis⁃related arthritis, or psoriatic arthritis: 6⁃year efficacy and safety data from an open⁃label trial［J］. Arthritis Res Ther, 2019,21（1）:125. doi: 10.1186/s13075⁃019⁃1916⁃9.
［13］	鲁珊, 周薇, 张倩, 等. 幼年银屑病关节炎［J］. 中国当代儿科杂志, 2007,9（4）:339⁃342. doi: 10.3969/j.issn.1008⁃8830.2007. 04.014.
［14］	Hospach T, Glowatzki F, Blankenburg F, et al. Scoping review of biological treatment of deficiency of interleukin⁃36 receptor antagonist （DITRA） in children and adolescents［J］. Pediatr Rheumatol Online J, 2019,17（1）:37. doi: 10.1186/s12969⁃019⁃0338⁃1.
［15］	Papoutsaki M, Costanzo A, Mazzotta A, et al. Etanercept for the treatment of severe childhood psoriasis［J］. Br J Dermatol, 2006,154（1）:181⁃183. doi: 10.1111/j.1365⁃2133.2005.06982.x.
［16］	Fialová J, Vojáčková N, Vaňousová D, et al. Juvenile generalized pustular psoriasis treated with etanercept［J］. Dermatol Ther, 2014,27（2）:105⁃108. doi: 10.1111/dth.12065.
［17］	Armaroli G, Klein A, Ganser G, et al. Long⁃term safety and effectiveness of etanercept in JIA: an 18⁃year experience from the BiKeR registry［J］. Arthritis Res Ther, 2020,22（1）:258. doi: 10.1186/s13075⁃020⁃02326⁃5.
［18］	Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double⁃blind, phase 3 trial［J］. Lancet, 2017,390（10089）:40⁃49. doi: 10.1016/S0140⁃6736（17）31189⁃3.
［19］	Thaçi D, Papp K, Marcoux D, et al. Sustained long⁃term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double⁃blind, phase III study［J］. Br J Dermatol, 2019,181（6）:1177⁃1189. doi: 10.1111/bjd.18029.
［20］	Horneff G, Seyger M, Arikan D, et al. Safety of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis⁃related arthritis, psoriasis, and crohn′s disease［J］. J Pediatr, 2018,201:166⁃175. doi: 10.1016/j.jpeds.2018.05.042.
［21］	Craiglow BG, Boyden LM, Hu R, et al. CARD14⁃associated papulosquamous eruption: a spectrum including features of psoriasis and pityriasis rubra pilaris［J］. J Am Acad Dermatol, 2018,79（3）:487⁃494. doi: 10.1016/j.jaad.2018.02.034.
［22］	Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate⁃to⁃severe plaque psoriasis: results of the randomized phase 3 CADMUS study［J］. J Am Acad Dermatol, 2015,73（4）:594⁃603. doi: 10.1016/j.jaad.2015.07.002.
［23］	Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate⁃to⁃severe plaque psoriasis in paediatric patients （≥ 6 to < 12 years of age）: efficacy, safety, pharmacokinetic and biomarker results from the open⁃label CADMUS Jr study［J］. Br J Dermatol, 2020,183（4）:664⁃672. doi: 10.1111/bjd.19018.
［24］	Magnolo N, Kingo K, Laquer V, et al. Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 52⁃week results from a randomized trial［C/OL］//American Academy of Dermatology Virtual Meeting Experience（AAD VMX）, online, 2021［2021⁃10⁃19］. https://eposters.aad.org/abstracts/26860.
［25］	Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52⁃week results from a Phase 3 double⁃blind randomized, controlled trial［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:938⁃947. doi: 10.1111/jdv.17002.
［26］	谢辉, 牛美丽, 王新慧, 等. 司库奇尤单抗治疗儿童银屑病六例疗效评价［J］. 中国麻风皮肤病杂志, 2021,37（3）:157⁃159,162. doi: 10.12144/zgmfskin202103157.
［27］	孙勇虎, 张福仁. 白介素17A拮抗剂治疗儿童银屑病一例并文献复习［J］. 中国麻风皮肤病杂志, 2021,37（1）:30⁃31,36. doi: 10.12144/zgmfskin202101030.
［28］	Paller AS, Seyger M, Alejandro Magariños G, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double⁃blind, placebo⁃controlled study in paediatric patients with moderate⁃to⁃severe plaque psoriasis （IXORA⁃PEDS）［J］. Br J Dermatol, 2020,183（2）:231⁃241. doi: 10.1111/bjd.19147.
［29］	Ferrara G, Losi M, D′Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study［J］. Lancet, 2006,367（9519）:1328⁃1334. doi: 10.1016/S0140⁃6736（06）68579⁃6.
［30］	Bagel J. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis［J］. J Drugs Dermatol, 2011,10（4）:366⁃371.
［31］	Gambichler T, Tigges C, Scola N, et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks［J］. Br J Dermatol, 2011,164（6）:1383⁃1386. doi: 10.1111/j.1365⁃2133. 2011.10358.x.
［32］	Wolf P, Weger W, Legat FJ, et al. Treatment with 311⁃nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab⁃treated patients: a randomized intraindividual trial［J］. Br J Dermatol, 2012,166（1）:147⁃153. doi: 10.1111/j.1365⁃2133.2011.10616.x.
［33］	Lynde CW, Gupta AK, Guenther L, et al. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept［J］. J Dermatolog Treat, 2012,23（4）:261⁃267. doi: 10.3109/09546634. 2011.607795.
［34］	Park KK, Wu JJ, Koo J. A randomized, ′head⁃to⁃head′ pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B （NB⁃UVB） phototherapy in obese psoriasis patients［J］. J Eur Acad Dermatol Venereol, 2013,27（7）:899⁃906. doi: 10.1111/j.1468⁃3083.2012.04611.x.
［35］	Cather JC, Crowley JJ. Use of biologic agents in combination with other therapies for the treatment of psoriasis［J］. Am J Clin Dermatol, 2014,15（6）:467⁃478. doi: 10.1007/s40257⁃014⁃0097⁃1.
［36］	Heinecke GM, Luber AJ, Levitt JO, et al. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center［J］. J Drugs Dermatol, 2013,12（10）:1098⁃1102.
［37］	Bissonnette R, Maari C, Barber K, et al. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab［J］. J Eur Acad Dermatol Venereol, 2015,29（8）:1576⁃1581. doi: 10.1111/jdv.12943.
［38］	Downs AM. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab［J］. Br J Dermatol, 2010,163（2）:433⁃434. doi: 10.1111/j.1365⁃2133.2010. 09832.x.
［39］	Hu Y, Chen Z, Gong Y, et al. A review of switching biologic agents in the treatment of moderate⁃to⁃severe plaque psoriasis［J］. Clin Drug Investig, 2018,38（3）:191⁃199. doi: 10.1007/s40261⁃017⁃0603⁃3.
［40］	Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double⁃blind, phase III NAVIGATE trial［J］. Br J Dermatol, 2018,178（1）:114⁃123. doi: 10.1111/bjd.15750.
［41］	Sator P, Richter L, Saxinger W, et al. Adalimumab in the treatment of moderate⁃to⁃severe chronic plaque psoriasis in patients switching from other biologics［J］. J Eur Acad Dermatol Venereol, 2015,29（9）:1742⁃1749. doi: 10.1111/jdv.12981.
［42］	Lansang P, Bergman JN, Fiorillo L, et al. Management of pediatric plaque psoriasis using biologics［J］. J Am Acad Dermatol, 2020,82（1）:213⁃221. doi: 10.1016/j.jaad.2019.05.056.
［43］	Smith CH, Yiu Z, Bale T, et al. British association of dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update［J］. Br J Dermatol, 2020,183（4）:628⁃637. doi: 10.1111/bjd. 19039.
［44］	Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics［J］. J Am Acad Dermatol, 2019,80（4）:1029⁃1072. doi: 10.1016/j.jaad.2018.11.057.
［45］	Huber F, Ehrensperger B, Hatz C, et al. Safety of live vaccines on immunosuppressive or immunomodulatory therapy⁃a retrospective study in three Swiss Travel Clinics［J］. J Travel Med, 2018,25（1）. doi: 10.1093/jtm/tax082.
［46］	Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature［J］. J Am Acad Dermatol, 2017,77（1）:88⁃97. doi: 10.1016/j.jaad.2017.01.037.

[1]	Li Yan, Li Ming, Xu Wei, Li Linfeng. Efficacy of fluticasone propionate cream alone or in combination with calcipotriol ointment in the treatment of mild to moderate plaque psoriasis: a randomized self-controlled study [J]. Chinese Journal of Dermatology, 2022, 0(4): 20210246-e20210246.
[2]	Wang Jiaqi, Wang Ping, Li Liuyu, Fan Qimin, Zhu Mengyan, Wang Yanqing, Zhou Hongyu, Shen Hong, Xu Ai′e. Cutaneous hypopigmented lymphoproliferative disorders: a clinicopathological study of 41 cases [J]. Chinese Journal of Dermatology, 2022, 55(2): 110-115.
[3]	He Rui, Zhang Bin, Li Li, Wei Li, Zhang Nan, Yu Tong, Yin Jie, Xu Zigang, Ma Lin. Clinical efficacy and safety of topical sirolimus in the treatment of 19 cases of superficial vascular malformation in children [J]. Chinese Journal of Dermatology, 2022, 55(2): 129-134.
[4]	Wang Yue, Yan Yulin. Analysis of acitretin-related adverse reactions and reasons for drug discontinuation in 171 patients with psoriasis vulgaris [J]. Chinese Journal of Dermatology, 2022, 0(2): 20200867-e20200867.
[5]	Li Sai, Xue Huazhong, Zhang Shuwen, Jiang Juan, Qi Shuzhen, Zhao Yuanyuan, Zhang Jinping, Sha Zhong, Le Wenjing, Wang Biwei, Zhao Shixuan, Zhu Xiaofeng, Su Xiaohong. Doxycycline-moxifloxacin sequential therapy for Mycoplasma genitalium urethritis/cervicitis: a clinical observation [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210631-e20210631.
[6]	Ou Min, Yan Yunling, Zheng Baoqing, Wang Xiaohua. Correlations between psoriasis and obesity [J]. Chinese Journal of Dermatology, 2022, 55(2): 181-184.
[7]	Bao Shijie, Cheng Yang, Yan Ying, Fan Fang, Gao Tingting, Feng Xiaolan, Zheng Liang, Lei Wei, Huang Qinsi, Zhang Weiming, Zhou Xiaoyong. A comparative study of human immunoglobulin versus recombinant human tumor necrosis factor-α receptor Ⅱ:IgG Fc fusion protein in the treatment of toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2022, 55(2): 153-156.
[8]	Zhao Ying, Wang Juanjuan, Ji Jiang, Su Wenxing, Wei Yuqian, Leng Hong, Ding Yujie, Shi Xin. Interleukin-17A-mediated psoriasis and cardiovascular comorbidities [J]. Chinese Journal of Dermatology, 2022, 55(1): 76-79.
[9]	Guo Jing, Yang Jingyu, Ding Li, Liu Mingming, Hou Jingmei, Pu Xiaoxia, Sun Jiayu, Li Xianghua. Efficacy of long-pulsed 1 064-nm Nd:YAG laser combined with a topical emulsion containing Camellia reticulata and Radix Notoginseng in the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(1): 61-64.
[10]	Kong Xue, Shi Dongmei, Liu Weida. Application of antifungal agents in special populations [J]. Chinese Journal of Dermatology, 2022, 55(1): 80-83.
[11]	Chinese Society of Dermatology, China Dermatologist Association. Consensus on the diagnosis and treatment of autoimmune subepidermal bullous diseases （2022） [J]. Chinese Journal of Dermatology, 2022, 55(1): 1-11.
[12]	Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210420-e20210420.
[13]	Gao Rong, Zhang Lan, Li Zhengxiao. Biological agents in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis [J]. Chinese Journal of Dermatology, 2022, 55(1): 72-75.
[14]	Guo Wei, Zhao Tao, Guo Weinan, Ma Cuiling, Gao Tianwen, Zhao Jianhong, Li Bing. Surgical treatment strategies and outcomes of early-stage nail apparatus melanoma: a retrospective analysis of 115 cases [J]. Chinese Journal of Dermatology, 2021, 54(9): 777-784.
[15]	Long Hai, Jiang Li, Qiu Yueqi, Yao Nan, Liu Licong, Xie Yuming, Xiong Feng, Tan Siqi, Kuang Qiqi, You Ruixuan, Chai Ke, Luo Xin, Long Haojun, Xin Yue, Guo Ziyu, Wang Jiaqi, Tan Yixin, Zhang Qing, Zhang Guiying, Li Yaping, Su Yuwen, Xiao Rong, Lu Qianjin, . Clinical analysis of 1 057 patients with critical illnesses in a dermatological ward [J]. Chinese Journal of Dermatology, 2021, 54(9): 790-797.

Treatment of pediatric psoriasis with biological agents: a Chinese expert consensus statement （2021）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［46］

Related Articles 15

Metrics

Comments

Recommended 10